Stockholm Myocardial Infarction With Nonobstructive Coronaries Study 3 (SMINC-3)
Primary Purpose
Myocardial Infarction With Nonobstructive Coronary Arteries
Status
Recruiting
Phase
Not Applicable
Locations
Sweden
Study Type
Interventional
Intervention
Cardiac magnetic resonance imaging to study coronary microvascular dysfunction
Sponsored by
About this trial
This is an interventional diagnostic trial for Myocardial Infarction With Nonobstructive Coronary Arteries
Eligibility Criteria
Inclusion Criteria:
- a suspected diagnosis of MINOCA or takotsubo syndrome with coronary angiography without diameter stenosis ≥50%
- age 35-80 years
- reading and writing proficiency in Swedish
Exclusion Criteria:
- Claustrofobia
- Arrythmia and/or pacemaker (atrial fibrillation and AV-block I- III)
- Asthma or severe chronic obstructive lung disease
- eGFR < 30 ml/min
- spontaneous coronary artery dissection
- acute pulmonary embolism
- acute myocardial infarction type 2
- cardiomyopathy other than takotsubo syndrome
- a previous myocardial infarction due to CAD
Sites / Locations
- Per TornvallRecruiting
Arms of the Study
Arm 1
Arm Type
Other
Arm Label
Patients with MINOCA undergoing CMR
Arm Description
Patients will be their own controls
Outcomes
Primary Outcome Measures
Diagnostic yield
To increase the diagnostic yield of CMR imaging in MINOCA as a working diagnosis
Secondary Outcome Measures
Prevalence of CMD in MINOCA
To determine the proportion of patients with the working diagnosis of MINOCA who have CMD.
Prevalence of CMD in different final MINOCA diagnoses
To study the proportions of CMD in patients with a CMR imaging diagnosis of myocardial infarction, Takotsubo, respectively myocarditis and compare them with the results from a healthy control group
Angina pectoris
To investigate the occurrence of angina pectoris before inclusion and after 3 months and relate it to CMD
Full Information
NCT ID
NCT05426408
First Posted
June 10, 2022
Last Updated
March 14, 2023
Sponsor
Karolinska Institutet
Collaborators
Region Stockholm
1. Study Identification
Unique Protocol Identification Number
NCT05426408
Brief Title
Stockholm Myocardial Infarction With Nonobstructive Coronaries Study 3
Acronym
SMINC-3
Official Title
Stockholm Myocardial Infarction With Nonobstructive Coronaries Study 3 - Pilot Study of Prevalence of Coronary Microvascular Dysfunction in Myocardial Infarction With Nonobstructive Coronary Arteries
Study Type
Interventional
2. Study Status
Record Verification Date
March 2023
Overall Recruitment Status
Recruiting
Study Start Date
November 1, 2022 (Actual)
Primary Completion Date
December 31, 2023 (Anticipated)
Study Completion Date
March 31, 2024 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Karolinska Institutet
Collaborators
Region Stockholm
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
The present pilot study will investigate the prevalence of CMD in an unselected cohort of patients with the working diagnosis MINOCA and to study if the diagnostic yield can be improved by adding adenosine to the CMR investigation. Patient will be their own controls.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Myocardial Infarction With Nonobstructive Coronary Arteries
7. Study Design
Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
Patients will be their own controls
Masking
None (Open Label)
Masking Description
The investigators who will perform the evaluation of the CMR investigations will be blinded to all clinical data.
Allocation
N/A
Enrollment
85 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Patients with MINOCA undergoing CMR
Arm Type
Other
Arm Description
Patients will be their own controls
Intervention Type
Diagnostic Test
Intervention Name(s)
Cardiac magnetic resonance imaging to study coronary microvascular dysfunction
Intervention Description
Myocardial perfusion mapping will be investigated after administration of adenosine
Primary Outcome Measure Information:
Title
Diagnostic yield
Description
To increase the diagnostic yield of CMR imaging in MINOCA as a working diagnosis
Time Frame
Through investigation completion, usually 2 hours
Secondary Outcome Measure Information:
Title
Prevalence of CMD in MINOCA
Description
To determine the proportion of patients with the working diagnosis of MINOCA who have CMD.
Time Frame
Through investigation completion, usually 2 hours
Title
Prevalence of CMD in different final MINOCA diagnoses
Description
To study the proportions of CMD in patients with a CMR imaging diagnosis of myocardial infarction, Takotsubo, respectively myocarditis and compare them with the results from a healthy control group
Time Frame
Through investigation completion, usually 2 hours
Title
Angina pectoris
Description
To investigate the occurrence of angina pectoris before inclusion and after 3 months and relate it to CMD
Time Frame
3 Months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
35 Years
Maximum Age & Unit of Time
79 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
a suspected diagnosis of MINOCA or takotsubo syndrome with coronary angiography without diameter stenosis ≥50%
age 35-80 years
reading and writing proficiency in Swedish
Exclusion Criteria:
Claustrofobia
Arrythmia and/or pacemaker (atrial fibrillation and AV-block I- III)
Asthma or severe chronic obstructive lung disease
eGFR < 30 ml/min
spontaneous coronary artery dissection
acute pulmonary embolism
acute myocardial infarction type 2
cardiomyopathy other than takotsubo syndrome
a previous myocardial infarction due to CAD
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Per Tornvall, MD
Phone
+468616100
Email
per.tornvall@ki.se
First Name & Middle Initial & Last Name or Official Title & Degree
Peder Sörensson, MD
Phone
+46812370000
Email
perder.sorensson@regionstockholm.se
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Per Tornvall, MD
Organizational Affiliation
Karolinska Instítutet
Official's Role
Principal Investigator
Facility Information:
Facility Name
Per Tornvall
City
Stockholm
ZIP/Postal Code
11551
Country
Sweden
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Per Tornvall
Phone
+46722180560
Email
per.tornvall@ki.se
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Stockholm Myocardial Infarction With Nonobstructive Coronaries Study 3
We'll reach out to this number within 24 hrs